Recombinant Llama Anti-BMP4 Single Domain Antibody (C8) (CAT#: HPAB-0355-YC-VHH)

Provided are anti-BMP4 antibodies binding to a conformational epitope located within the BMPRla binding site of BMP4 and pharmaceutical uses thereof.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 Anti-BMP4 VHH specificity to the different BMPs.

Figure 1 Anti-BMP4 VHH specificity to the different BMPs.

Phosphorylation of SMAD1/5/8 in EPC2-hERT cells after activation with 100 ng/mL of human BMP4 in the presence of 5 mg/mL VHHs.

Calpe, S., Wagner, K., El Khattabi, M., Rutten, L., Zimberlin, C., Dolk, E., ... & Krishnadath, K. K. (2015). Effective inhibition of bone morphogenetic protein function by highly specific llama-derived antibodies. Molecular cancer therapeutics, 14(11), 2527-2540.

FuncS

Figure 2 Anti-BMP4 VHH specificity to the different BMPs.

Figure 2 Anti-BMP4 VHH specificity to the different BMPs.

C2C12 cells were activated with human BMPs in the presence or absence of 5 mg/mL of VHHs or human Fc-Noggin.

Calpe, S., Wagner, K., El Khattabi, M., Rutten, L., Zimberlin, C., Dolk, E., ... & Krishnadath, K. K. (2015). Effective inhibition of bone morphogenetic protein function by highly specific llama-derived antibodies. Molecular cancer therapeutics, 14(11), 2527-2540.

Activ

Figure 3 IC50 curves of VHH biheads and monoheads.

Figure 3 IC50 curves of VHH biheads and monoheads.

C2C12 cells were activated with human BMP4 at 5 ng/mL with increasing concentrations of VHHs.

Calpe, S., Wagner, K., El Khattabi, M., Rutten, L., Zimberlin, C., Dolk, E., ... & Krishnadath, K. K. (2015). Effective inhibition of bone morphogenetic protein function by highly specific llama-derived antibodies. Molecular cancer therapeutics, 14(11), 2527-2540.

SPR

Figure 4 Kinetic analysis for BMP binding.

Figure 4 Kinetic analysis for BMP binding.

Binding of VHHs to the different BMPs was tested in a direct SPR assay.

Calpe, S., Wagner, K., El Khattabi, M., Rutten, L., Zimberlin, C., Dolk, E., ... & Krishnadath, K. K. (2015). Effective inhibition of bone morphogenetic protein function by highly specific llama-derived antibodies. Molecular cancer therapeutics, 14(11), 2527-2540.

SPR

Figure 5 Kinetic analysis for BMP binding.

Figure 5 Kinetic analysis for BMP binding.

Epitope binning of VHH-coated chip plates. BMP4 (1.0 mg/mL) was injected on the chip followed by the injection of a second VHH (2.0 mg/mL) or the corresponding controls.

Calpe, S., Wagner, K., El Khattabi, M., Rutten, L., Zimberlin, C., Dolk, E., ... & Krishnadath, K. K. (2015). Effective inhibition of bone morphogenetic protein function by highly specific llama-derived antibodies. Molecular cancer therapeutics, 14(11), 2527-2540.

FuncS

Figure 6 HADDOCK docking of the VHHs to BMP4 binding.

Figure 6 HADDOCK docking of the VHHs to BMP4 binding.

Function of the generated mutant variants in inhibiting ID1 promoter activity in C2C12 cells after stimulation with BMP4 (5 ng/mL) for 16 hours.

Calpe, S., Wagner, K., El Khattabi, M., Rutten, L., Zimberlin, C., Dolk, E., ... & Krishnadath, K. K. (2015). Effective inhibition of bone morphogenetic protein function by highly specific llama-derived antibodies. Molecular cancer therapeutics, 14(11), 2527-2540.


Specifications

  • Immunogen
  • BMP4
  • Host Species
  • Llama
  • Derivation
  • The VHH library
  • Type
  • Llama VHH
  • Specificity
  • Human BMP4
  • Species Reactivity
  • Human
  • Clone
  • C8
  • Applications
  • Functional Assay, Surface plasmon resonance, Activation
  • Related Disease
  • Colorectal cancer

Applications

  • Application Notes
  • The antibody was validated for Functional Assay, Surface plasmon resonance, Activation. For details, refer to Published Data.

Target

  • Alternative Names
  • Bone Morphogenetic Protein 4; Bone Morphogenetic Protein 2B; BMP-2B; BMP2B; BMP-4; BMP2B1; MCOPS6; OFC11; Zyme; DVR4

Related Resources

  • Related Signaling Pathways

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "BMP4"

Recombinant Antibody

Single-domain Antibody

Rabbit Monoclonal Antibody

CAT Product Name Application Type
MOR-0367 Hi-Affi™ Rabbit Anti-BMP4 Recombinant Antibody (clone DS367AB) WB, IHC, ICC, IP, FC Rabbit IgG

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for HPAB-0355-YC-VHH. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare